Register for Updates
By registering for updates, you will receive periodic communications from Gilead providing you with the latest information about HIV products and HIV disease and treatment issues.
Please enter your information in the form below. Fields marked with an asterisk (*) are required to submit the form.
|
|
Gender*
|
 |
First name*
|
Last name*
|
|
E-mail address*
|
|
Re-enter e-mail address*
|
|
Street address*
|
|
|
|
|
Physician's Name*
|
I do not have a physician
|
|
| I am a*: |
|
Patient |
|
|
|
Healthcare professional |
|
Family member/Friend of a person living with HIV
|
| |
|
|
Treatment educator/Case manager |
|
Other |
|
|
|
Gilead respects the privacy of your personal health information. Gilead, and companies providing services to Gilead, may use the information that you provide to send you marketing or informational materials, analyze and use your information to improve or develop products, services, and programs, and contact you about marketing programs or research and health topics that may be of interest to you.
Gilead, or its contracted third parties, will not sell or rent your personally identifiable information. For more information regarding our Privacy Policy, please click here.
To unsubscribe from future updates and remove your name from our mailing list, please click here.
|
|
|
|
|
|
|
Patients should read the Patient Information, including "What is the most important information I should know about TRUVADA?". It is important that you discuss your treatment options and any questions that you may have with your healthcare provider.
Please read the Full Prescribing Information for TRUVADA, EMTRIVA, and VIREAD, including Boxed WARNINGS.
Please read the Full Prescribing Information for TRUVADA, ATRIPLA, EMTRIVA, and VIREAD, including Boxed WARNINGS.
*Synovate Healthcare Data; U.S. HIV Monitor, Q1, 2010.